Announcements Trials
Browse Landscape

Phase

Phase 2 37Phase 1 9Phase 3 4Phase 1/2 4Phase NA 3Phase 2/3 3

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Other neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Older Patients 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Cisplatin 30Magnetic Resonance Spectroscopy 23Carboplatin 23pembrolizumab 21Paclitaxel 20Gemcitabine 19Specimen Handling 16Dexamethasone 15Radiotherapy 14Nivolumab 14Drug Therapy 14Doxorubicin 14Bevacizumab 14atezolizumab 13Oxaliplatin 13Cyclophosphamide 13Radiation 11Pemetrexed 11Cytarabine 11venetoclax 10Vincristine 10Prednisone 10Docetaxel 10Capecitabine 10Trastuzumab 9Temozolomide 8Rituximab 8Platinum 8Ipilimumab 8Fluorouracil 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Busulfan × 1 year × Clear all
NCT04217278 2026-05-05

COSI

University of Birmingham

Phase 2/3 Active not recruiting
333 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04708054 2026-02-19

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

M.D. Anderson Cancer Center

Phase 2/3 Recruiting
324 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT07052422 2025-07-04

VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT

Nanfang Hospital, Southern Medical University

Phase 2/3 Not yet recruiting
160 enrolled
Other neoplasm

Older Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡